Page 12 - Alkermes News Today

News and commentary from the psychiatry world

Primecap Management Co. CA lessened its holdings in shares of Alkermes plc (NASDAQ:ALKS – Free Report) by 8.2% in the 4th quarter, Holdings Channel.com reports. The firm owned 3,565,625 shares of the company’s stock after selling 316,605 shares during the quarter. Primecap Management Co. CA’s holdings in Alkermes were worth $98,910,000 as of its most […]

Shares of Alkermes plc (NASDAQ:ALKS – Get Free Report) have earned an average recommendation of “Moderate Buy” from the ten analysts that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and six have issued a buy recommendation on […]

/PRNewswire/ -- The "Long-Acting Drug Delivery Technologies and Services Market: A Global and Regional Analysis, 2023-2033" report has been added to...

Equal Opportunity and Respect: Diversity, Inclusion and Belonging at ...

Novo Nordisk’s €2 billion project in Clondalkin is tipped to create 1,100 jobs

News of new factory comes after Danish group announced in December the purchase of drug manufacturing plant in Athlone in order to keep up with demand for weight-loss drugs

Alkermes (ALKS) reachead $27.92 at the closing of the latest trading day, reflecting a +1.34% change compared to its last close.

Dublin, Dec. 22, 2023 (GLOBE NEWSWIRE) -- The